Zika Virus Disease Market

Market Overview:

The Zika virus disease market reached a value of USD 13.3 Billion across the top 7 markets (US, EU4, UK, and Japan) in ​2024​. Looking forward, IMARC Group expects the top 7 major markets to reach USD 21.3 Billion by 2035, exhibiting a growth rate (CAGR) of 4.41% during ​2025-2035​.

The Zika virus disease market has been comprehensively analyzed in IMARC's new report titled "Zika Virus Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast ​2025-2035​". Zika virus disease is a viral disease spread by mosquitoes, which include Aedes mosquitoes. Zika may also be transmitted through sexual intercourse, blood transfusions, and from mother to child during pregnancy. Most people who are infected with Zika will not experience symptoms or only minimal symptoms. The most frequent signs are fever, rash, headache, joint and muscle pain, red eyes, and general malaise. Such symptoms usually persist for two to seven days. Pregnancy-related Zika virus disease poses a critical risk as it might result in major birth abnormalities like microcephaly (clinically, small brain and head with possible facial anomaly) and various other neurological pathologies among babies. Its identification often comprises in-depth clinical diagnosis and physical check-up. The medical practitioner can also perform molecular tests, including polymerase chain reaction, to search for the presence of Zika virus genetic material in a blood or urine sample. In addition, IgM antibody testing is performed to identify certain Zika virus IgM antibodies in the blood, which usually appear within the first week after symptoms start and may last for several weeks or months.

The escalating prevalence of the Zika virus that is spread through the bite of infected Aedes mosquitoes, such as Aedes aegypti and Aedes albopictus is primarily driving the Zika virus disease market. In addition to this, the inflating utilization of broad-spectrum antiviral drugs, like favipiravir, ribavirin, and sofosbuvir, to inhibit viral replication and manage symptoms in individuals suffering from the illness, is also creating a positive outlook for the market. Moreover, the widespread adoption of RNA-based therapies, since they offer several advantages for treating and preventing Zika virus disease is further bolstering the market growth. These therapies include messenger RNA (mRNA) vaccines, small interfering RNA (siRNA), and antisense oligonucleotides (ASOs) designed to target viral replication. Apart from this, the rising usage of plasmapheresis that helps lower circulating Zika virus particles in critically ill patients, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of vesicular stomatitis virus (VSV) vaccines, which can induce both humoral and cellular immunity, providing robust and long-lasting protection against Zika virus is expected to drive the Zika virus disease market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the Zika virus disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Zika virus disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Zika virus disease market in any manner.

Recent Developments:

• In March 2024, Valneva SE announced the start of a Phase 1 clinical trial to investigate the safety and immunogenicity of VLA1601, its second-generation adjuvanted inactivated vaccine candidate against the Zika virus.

Drugs:

VLA1601 is a highly purified inactivated vaccine candidate against the Zika virus disease. The vaccine causes the body to develop antibodies against the Zika virus, specifically targeting viral proteins E, prM, and NS1. These antibodies can neutralize the virus, preventing it from infecting cells. In addition to antibodies, the vaccination stimulates a T cell response, which is a crucial component of the immune system that aids in the elimination of infected cells.

TV003 is a tetravalent live-attenuated dengue vaccine developed by the National Institute of Allergy and Infectious Diseases (NIAID). It contains weakened forms of all four dengue virus serotypes, designed to stimulate a robust immune response without causing disease. Upon administration, TV003 mimics natural dengue infection, prompting the immune system to produce neutralizing antibodies and memory B cells against each serotype.

Time Period of the Study

• Base Year: 2024
• Historical Period: ​2019-2024​
• Market Forecast: ​2025-2035​

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Zika virus disease market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Zika virus disease market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Zika virus disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the Zika virus disease market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the Zika virus disease market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the Zika virus disease market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (​2019-2035​) of Zika virus disease across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of Zika virus disease by age across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of Zika virus disease by gender across the seven major markets?
• How many patients are diagnosed (​2019-2035​) with Zika virus disease across the seven major markets?
• What is the size of the Zika virus disease patient pool (​2019-2024​) across the seven major markets?
• What would be the forecasted patient pool (​2025-2035​) across the seven major markets?
• What are the key factors driving the epidemiological trend of Zika virus disease?
• What will be the growth rate of patients across the seven major markets?

Zika Virus Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for Zika virus disease drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Zika virus disease market?
• What are the key regulatory events related to the Zika virus disease market?
• What is the structure of clinical trial landscape by status related to the Zika virus disease market?
• What is the structure of clinical trial landscape by phase related to the Zika virus disease market?
• What is the structure of clinical trial landscape by route of administration related to the Zika virus disease market?